

Intersect ENT Named One of the “Fierce 15” Most Promising Private Companies by *FierceMedicalDevices*

Menlo Park, Calif. – Oct. 15, 2013 – Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and their patients, today announced that the company has been named by *FierceMedicalDevices* as one of the 2013 “Fierce 15”, designating it as one of the most promising private device and diagnostic companies in the industry. The award celebrates the spirit of being “fierce”, championing innovation and creativity.

“These companies represent some of the best and brightest in the device and diagnostics industries today,” *FierceMedicalDevices* Editor Mark Hollmer said. “They’ll be producing big things in the months and years ahead.”

“We are honored to be included in *FierceMedicalDevices*’ list of the most promising privately held companies,” said Lisa Earnhardt, president and CEO of Intersect ENT. “We are proud of our track record of success in improving outcomes for sinus sufferers, and we look forward to developing less invasive, more cost effective solutions that bring value to patients, physicians and the health care system alike.”

Intersect ENT’s PROPEL[®] and PROPEL[®] mini implants are used in conjunction with sinus surgery. The products release mometasone furoate, an advanced steroid with anti-inflammatory properties, directly into the sinus lining, then dissolves. Use of PROPEL maintains the opening created in surgery leading to reduced need for oral medication and additional surgical procedures. The company is also studying a novel in-office solution for patients suffering from chronic sinusitis in a randomized clinical trial called the RESOLVE Study (www.ResolveSinusStudy.com). Promising results from a pilot study of the device were reported last month.

Chronic sinusitis is a condition in which patients’ sinuses become swollen and inflamed, leading to difficulty breathing, facial pain or headache, and reduced sense of smell and taste. The condition is common, affecting 31 million people in the U.S., and greatly impacts quality of life. Chronic sinusitis often requires a complex combination of surgical and medical treatments. Each year, 500,000 patients undergo sinus surgery to treat the condition.

About Intersect ENT

Intersect ENT Inc., located in Menlo Park, Calif., is an innovator in local drug delivery focused on advancing clinically proven therapy solutions that improve quality of life for patients with ear, nose and throat conditions. The company’s initial products, the PROPEL and PROPEL mini dissolvable steroid-releasing implants, are the only products backed by Level 1-A clinical evidence to improve sinus surgery outcomes for patients suffering from chronic sinusitis. Chronic sinusitis is a common condition that affects one out of seven adults in the U.S. and greatly impacts quality of life. The company holds twenty-one issued U.S. patents and more than 80 patents and pending applications worldwide. Intersect ENT is backed by Kleiner Perkins Caufield & Byers; U.S. Venture Partners; PTV Sciences; Norwest Venture Partners, and Medtronic. For more information please visit www.intersectENT.com.

About *FierceMedicalDevices*

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.

An internationally recognized newsletter reaching more than 30,000 medical device and diagnostics industry professionals, *FierceMedicalDevices* provides subscribers with an authoritative analysis of the day’s top stories. Every year, *FierceMedicalDevices* evaluates dozens of private companies from around the world for its annual Fierce 15 list, which is based on factors including technology strength, partnerships, venture backers and a competitive market position.

A complete list of “Fierce 15” companies – the online newsletter’s second annual selection – is available online at FierceMedicalDevices.com.

FierceMedicalDevices is the med tech industry's daily monitor – a free email newsletter and web resource providing the latest news, articles and resources related to M&A, clinical trials, FDA approval and regulation, and more. Signing up is free.

#

2013 © Intersect ENT Inc. All rights reserved. INTERSECT ENT® and PROPEL® are trademarks of Intersect ENT, Inc.

Patients with Chronic Sinusitis should consult their ENT surgeon for a full discussion of risks and benefits to determine whether this product is the right choice.

Media Contact:
Nicole Osmer
650.454.0504
nicole@nicoleosmer.com